T. M. O'Brien

Articles by T. M. O'Brien

Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions

ByS. A. Gregory,M. Coleman,A. Ali,T. M. O'Brien,A. Subramanian,L. Kostakoglu,S. J. Goldsmith,N. Valente,J. P. Leonard

March 1st 2001

Relapsed or refractory low-grade non-Hodgkin’s lymphoma (NHL) and transformed low-grade NHL are incurable diseases. Tositumomab/iodine-131 tositumomab (Bexxar) is a novel

Latest Updated Articles

Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions
Published: March 1st 2001 | Updated:

T. M. O'Brien

Articles by T. M. O'Brien

Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions

Latest Updated Articles

Trending on CancerNetwork

Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC

ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer

Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies

LAURA Trial, SINDAS Trial, NORTHSTAR Trial, and LONESTAR Trial